

2020 Low Back Pain Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs

<https://marketpublishers.com/r/235090F50D0DEN.html>

Date: February 2020

Pages: 104

Price: US\$ 1,999.00 (Single User License)

ID: 235090F50D0DEN

Abstracts

The 2020 Low Back Pain pipeline report presents a comprehensive overview of the research and development of Low Back Pain drug candidates. It presents drugs in development that could potentially reach the market in the next 5 to 10 years: One drug in Research phase, three drugs in pre-clinical phase, five drugs in Phase 1, 13 drugs in Phase 2, four drugs in Phase 3 and one drug in Pre-registration phase

As of February 2020, the Low Back Pain pipeline remains robust with 27 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Low Back Pain treatment. Diverse types of targeted therapies are being explored through clinical trials including Adenosine A2A receptor agonists; adenosine receptors antagonist; Cannabinoid receptor CB1 antagonists; Cannabinoid receptor CB2 antagonists; Cannabinoid receptor modulators; Cyclooxygenase inhibitors; farnesyl pyrophosphate synthase (FPPS) inhibitor; Kruppel-like Factors (KLF) 6, 9 and 15, transcription factors inhibitor; muscarinic antagonist; Nerve growth factor inhibitors; nuclear factor kappa B (NFkB) inhibitor; Opioid kappa receptor antagonists; Opioid mu receptor agonists; Osteoclast inhibitors; Sodium channel antagonists; tropomyosin receptor kinase A (TrkA) inhibitor.

The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Low Back Pain drug development history, latest news, and other developments.

It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it

enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.

PUBLISHER EXPERTISE

VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.

SCOPE:

The report scope comprises of both pre-clinical phase and clinical phase development drugs for Low Back Pain development

Low Back Pain pipeline compounds and molecules under study by both large scale and small companies are included in the report

Low Back Pain pipeline across different phases including discovery, research, and pre-clinical stage, phase 1, phase 2, phase 3 and pre-registration phases are covered

Drug profile comprising of current development status, regulatory progress, companies, sponsors, mechanism of action, route of administration, molecule, and discovery details are covered

Further, orphan drug status, fast track designation, different grants awarded and special status for Low Back Pain pipeline candidates included

Business overview and snapshot of all companies involved in Low Back Pain pipeline are included

Latest market and pipeline developments are provided in the report

Low Back Pain pipeline companies included in the report are- Ache Laboratorios Farmaceuticos SA, Adynxx Inc, Allodynic Therapeutics LLC, AnGes Inc, Axxsome

Therapeutics Inc, BioRestorative Therapies Inc, Bol Pharma, Camurus AB, Daewon Pharmaceutical Co Ltd, Frontier Biotechnologies Inc, Gador SA, Grunenthal GmbH, Hisamitsu Pharmaceutical Co Inc, Imbrium Therapeutics LP, Immune Pharmaceuticals Inc, Inspyr Therapeutics Inc, Intec Pharma Ltd, MD Biosciences GmbH, Mesoblast Ltd, Navipharma Co Ltd, Nektar Therapeutics, Pacira BioSciences Inc, Pfizer Inc, Stayble Therapeutics AB, Therapix Biosciences Ltd, WEX Pharmaceuticals Inc

Low Back Pain pipeline drugs profiled in the report include- (Orfenadrine, Acetaminophen, Caffeine, Diclofenac Sodium) Combination Drug, AYX2, ATNC05 (ALLOD-2), AMG0101, AXS-02 (disodium zoledronate tetrahydrate), BRTX-100, BOL-DP-o-04, CAM2038 (buprenorphine), DW340 (eperisone/ pelubiprofen), AB001, IG8801 (Olpadronic), GRT6005 (cebranopadol), HP-3150, IMB-110, lidocaine patch, Adenosine A2A receptor agonists for Low Back Pain, AP-THC, MD 22, MPC-06-ID, NVP-1203 (Aceclofenac/eperisone), oxycodol phosphate, Bupivacaine extended release, AK-1830, tanezumab (PF-4383119), STA363, THX-110 (Dronabinol and Palmitoylethanolamide), Tetrodotoxin (TTX)

Contents

1. TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2. EXECUTIVE SUMMARY

- 2.1 Report Scope and Research Methodology
- 2.2 Introduction to Low Back Pain Condition
- 2.3 Low Back Pain Pipeline Snapshot, 2020
- 2.4 Companies investing in Low Back Pain pipeline therapeutics
- 2.5 Phase wise Low Back Pain Pipeline Candidates
- 2.6 Most Researched Mechanism of Action of Low Back Pain Pipeline Products
- 2.7 Route of Administration of Low Back Pain Pipeline Drugs

3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT

- 3.1 Ache Laboratorios Farmaceuticos SA Overview, Contacts and ASD Pipeline Drugs
- 3.2 Adynxx Inc Overview, Contacts and ASD Pipeline Drugs
- 3.3 Allodynic Therapeutics LLC Overview, Contacts and ASD Pipeline Drugs
- 3.4 AnGes Inc Overview, Contacts and ASD Pipeline Drugs
- 3.5 Axsome Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
- 3.6 BioRestorative Therapies Inc Overview, Contacts and ASD Pipeline Drugs
- 3.7 Bol Pharma Overview, Contacts and ASD Pipeline Drugs
- 3.8 Camurus AB Overview, Contacts and ASD Pipeline Drugs
- 3.9 Daewon Pharmaceutical Co Ltd Overview, Contacts and ASD Pipeline Drugs
- 3.10 Frontier Biotechnologies Inc Overview, Contacts and ASD Pipeline Drugs
- 3.11 Gador SA Overview, Contacts and ASD Pipeline Drugs
- 3.12 Grunenthal GmbH Overview, Contacts and ASD Pipeline Drugs
- 3.13 Hisamitsu Pharmaceutical Co Inc Overview, Contacts and ASD Pipeline Drugs
- 3.14 Imbrium Therapeutics LP Overview, Contacts and ASD Pipeline Drugs
- 3.15 Immune Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
- 3.16 Inspyr Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
- 3.17 Intec Pharma Ltd Overview, Contacts and ASD Pipeline Drugs
- 3.18 MD Biosciences GmbH Overview, Contacts and ASD Pipeline Drugs
- 3.19 Mesoblast Ltd Overview, Contacts and ASD Pipeline Drugs
- 3.20 Navipharma Co Ltd Overview, Contacts and ASD Pipeline Drugs

- 3.21 Nektar Therapeutics Overview, Contacts and ASD Pipeline Drugs
- 3.22 Pacira BioSciences Inc Overview, Contacts and ASD Pipeline Drugs
- 3.23 Pfizer Inc Overview, Contacts and ASD Pipeline Drugs
- 3.24 Stayble Therapeutics AB Overview, Contacts and ASD Pipeline Drugs
- 3.25 Therapix Biosciences Ltd Overview, Contacts and ASD Pipeline Drugs
- 3.26 WEX Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs

4. ACTIVE PIPELINE DRUG DETAILS, 2020

- 4.1 (Orfenadrine, Acetaminophen, Caffeine, Diclofenac Sodium) Combination Drug Drug Details
 - 4.1.1 (Orfenadrine, Acetaminophen, Caffeine, Diclofenac Sodium) Combination Drug Current Status
 - 4.1.2 (Orfenadrine, Acetaminophen, Caffeine, Diclofenac Sodium) Combination Drug Drug Overview
 - 4.1.3 (Orfenadrine, Acetaminophen, Caffeine, Diclofenac Sodium) Combination Drug Mechanism of Action
 - 4.1.4 (Orfenadrine, Acetaminophen, Caffeine, Diclofenac Sodium) Combination Drug Licensing/Collaboration Companies
 - 4.1.5 (Orfenadrine, Acetaminophen, Caffeine, Diclofenac Sodium) Combination Drug Clinical Trials
- 4.2 AYX2 Drug Details
 - 4.2.1 AYX2 Current Status
 - 4.2.2 AYX2 Drug Overview
 - 4.2.3 AYX2 Mechanism of Action
 - 4.2.4 AYX2 Licensing/Collaboration Companies
 - 4.2.5 AYX2 Clinical Trials
- 4.3 ATNC05 (ALLOD-2) Drug Details
 - 4.3.1 ATNC05 (ALLOD-2) Current Status
 - 4.3.2 ATNC05 (ALLOD-2) Drug Overview
 - 4.3.3 ATNC05 (ALLOD-2) Mechanism of Action
 - 4.3.4 ATNC05 (ALLOD-2) Licensing/Collaboration Companies
 - 4.3.5 ATNC05 (ALLOD-2) Clinical Trials
- 4.4 AMG0101 Drug Details
 - 4.4.1 AMG0101 Current Status
 - 4.4.2 AMG0101 Drug Overview
 - 4.4.3 AMG0101 Mechanism of Action
 - 4.4.4 AMG0101 Licensing/Collaboration Companies
 - 4.4.5 AMG0101 Clinical Trials

- 4.5 AXS-02 (disodium zoledronate tetrahydrate) Drug Details
 - 4.5.1 AXS-02 (disodium zoledronate tetrahydrate) Current Status
 - 4.5.2 AXS-02 (disodium zoledronate tetrahydrate) Drug Overview
 - 4.5.3 AXS-02 (disodium zoledronate tetrahydrate) Mechanism of Action
 - 4.5.4 AXS-02 (disodium zoledronate tetrahydrate) Licensing/Collaboration Companies
 - 4.5.5 AXS-02 (disodium zoledronate tetrahydrate) Clinical Trials
- 4.6 BRTX-100 Drug Details
 - 4.6.1 BRTX-100 Current Status
 - 4.6.2 BRTX-100 Drug Overview
 - 4.6.3 BRTX-100 Mechanism of Action
 - 4.6.4 BRTX-100 Licensing/Collaboration Companies
 - 4.6.5 BRTX-100 Clinical Trials
- 4.7 BOL-DP-o-04 Drug Details
 - 4.7.1 BOL-DP-o-04 Current Status
 - 4.7.2 BOL-DP-o-04 Drug Overview
 - 4.7.3 BOL-DP-o-04 Mechanism of Action
 - 4.7.4 BOL-DP-o-04 Licensing/Collaboration Companies
 - 4.7.5 BOL-DP-o-04 Clinical Trials
- 4.8 CAM2038 (buprenorphine) Drug Details
 - 4.8.1 CAM2038 (buprenorphine) Current Status
 - 4.8.2 CAM2038 (buprenorphine) Drug Overview
 - 4.8.3 CAM2038 (buprenorphine) Mechanism of Action
 - 4.8.4 CAM2038 (buprenorphine) Licensing/Collaboration Companies
 - 4.8.5 CAM2038 (buprenorphine) Clinical Trials
- 4.9 DW340 (eperisone/ pelubipufen) Drug Details
 - 4.9.1 DW340 (eperisone/ pelubipufen) Current Status
 - 4.9.2 DW340 (eperisone/ pelubipufen) Drug Overview
 - 4.9.3 DW340 (eperisone/ pelubipufen) Mechanism of Action
 - 4.9.4 DW340 (eperisone/ pelubipufen) Licensing/Collaboration Companies
 - 4.9.5 DW340 (eperisone/ pelubipufen) Clinical Trials
- 4.10 AB001 Drug Details
 - 4.10.1 AB001 Current Status
 - 4.10.2 AB001 Drug Overview
 - 4.10.3 AB001 Mechanism of Action
 - 4.10.4 AB001 Licensing/Collaboration Companies
 - 4.10.5 AB001 Clinical Trials
- 4.11 IG8801(Olpadronic) Drug Details
 - 4.11.1 IG8801(Olpadronic) Current Status
 - 4.11.2 IG8801(Olpadronic) Drug Overview

- 4.11.3 IG8801(Olpadronic) Mechanism of Action
- 4.11.4 IG8801(Olpadronic) Licensing/Collaboration Companies
- 4.11.5 IG8801(Olpadronic) Clinical Trials
- 4.12 GRT6005 (cebranopadol) Drug Details
 - 4.12.1 GRT6005 (cebranopadol) Current Status
 - 4.12.2 GRT6005 (cebranopadol) Drug Overview
 - 4.12.3 GRT6005 (cebranopadol) Mechanism of Action
 - 4.12.4 GRT6005 (cebranopadol) Licensing/Collaboration Companies
 - 4.12.5 GRT6005 (cebranopadol) Clinical Trials
- 4.13 HP-3150 Drug Details
 - 4.13.1 HP-3150 Current Status
 - 4.13.2 HP-3150 Drug Overview
 - 4.13.3 HP-3150 Mechanism of Action
 - 4.13.4 HP-3150 Licensing/Collaboration Companies
 - 4.13.5 HP-3150 Clinical Trials
- 4.14 IMB-110 Drug Details
 - 4.14.1 IMB-110 Current Status
 - 4.14.2 IMB-110 Drug Overview
 - 4.14.3 IMB-110 Mechanism of Action
 - 4.14.4 IMB-110 Licensing/Collaboration Companies
 - 4.14.5 IMB-110 Clinical Trials
- 4.15 lidocaine patch Drug Details
 - 4.15.1 lidocaine patch Current Status
 - 4.15.2 lidocaine patch Drug Overview
 - 4.15.3 lidocaine patch Mechanism of Action
 - 4.15.4 lidocaine patch Licensing/Collaboration Companies
 - 4.15.5 lidocaine patch Clinical Trials
- 4.16 Adenosine A2A receptor agonists for Low Back Pain Drug Details
 - 4.16.1 Adenosine A2A receptor agonists for Low Back Pain Current Status
 - 4.16.2 Adenosine A2A receptor agonists for Low Back Pain Drug Overview
 - 4.16.3 Adenosine A2A receptor agonists for Low Back Pain Mechanism of Action
 - 4.16.4 Adenosine A2A receptor agonists for Low Back Pain Licensing/Collaboration Companies
 - 4.16.5 Adenosine A2A receptor agonists for Low Back Pain Clinical Trials
- 4.17 AP-THC Drug Details
 - 4.17.1 AP-THC Current Status
 - 4.17.2 AP-THC Drug Overview
 - 4.17.3 AP-THC Mechanism of Action
 - 4.17.4 AP-THC Licensing/Collaboration Companies

- 4.17.5 AP-THC Clinical Trials
- 4.18 MD 22 Drug Details
 - 4.18.1 MD 22 Current Status
 - 4.18.2 MD 22 Drug Overview
 - 4.18.3 MD 22 Mechanism of Action
 - 4.18.4 MD 22 Licensing/Collaboration Companies
 - 4.18.5 MD 22 Clinical Trials
- 4.19 MPC-06-ID Drug Details
 - 4.19.1 MPC-06-ID Current Status
 - 4.19.2 MPC-06-ID Drug Overview
 - 4.19.3 MPC-06-ID Mechanism of Action
 - 4.19.4 MPC-06-ID Licensing/Collaboration Companies
 - 4.19.5 MPC-06-ID Clinical Trials
- 4.20 NVP-1203 (Aceclofenac/eperisone) Drug Details
 - 4.20.1 NVP-1203 (Aceclofenac/eperisone) Current Status
 - 4.20.2 NVP-1203 (Aceclofenac/eperisone) Drug Overview
 - 4.20.3 NVP-1203 (Aceclofenac/eperisone) Mechanism of Action
 - 4.20.4 NVP-1203 (Aceclofenac/eperisone) Licensing/Collaboration Companies
 - 4.20.5 NVP-1203 (Aceclofenac/eperisone) Clinical Trials
- 4.21 oxycodol phosphate Drug Details
 - 4.21.1 oxycodol phosphate Current Status
 - 4.21.2 oxycodol phosphate Drug Overview
 - 4.21.3 oxycodol phosphate Mechanism of Action
 - 4.21.4 oxycodol phosphate Licensing/Collaboration Companies
 - 4.21.5 oxycodol phosphate Clinical Trials
- 4.22 Bupivacaine extended release Drug Details
 - 4.22.1 Bupivacaine extended release Current Status
 - 4.22.2 Bupivacaine extended release Drug Overview
 - 4.22.3 Bupivacaine extended release Mechanism of Action
 - 4.22.4 Bupivacaine extended release Licensing/Collaboration Companies
 - 4.22.5 Bupivacaine extended release Clinical Trials
- 4.23 AK-1830 Drug Details
 - 4.23.1 AK-1830 Current Status
 - 4.23.2 AK-1830 Drug Overview
 - 4.23.3 AK-1830 Mechanism of Action
 - 4.23.4 AK-1830 Licensing/Collaboration Companies
 - 4.23.5 AK-1830 Clinical Trials
- 4.24 tanezumab (PF-4383119) Drug Details
 - 4.24.1 tanezumab (PF-4383119) Current Status

- 4.24.2 tanezumab (PF-4383119) Drug Overview
- 4.24.3 tanezumab (PF-4383119) Mechanism of Action
- 4.24.4 tanezumab (PF-4383119) Licensing/Collaboration Companies
- 4.24.5 tanezumab (PF-4383119) Clinical Trials
- 4.25 STA363 Drug Details
 - 4.25.1 STA363 Current Status
 - 4.25.2 STA363 Drug Overview
 - 4.25.3 STA363 Mechanism of Action
 - 4.25.4 STA363 Licensing/Collaboration Companies
 - 4.25.5 STA363 Clinical Trials
- 4.26 THX-110 (Dronabinol and Palmitoylethanolamide) Drug Details
 - 4.26.1 THX-110 (Dronabinol and Palmitoylethanolamide) Current Status
 - 4.26.2 THX-110 (Dronabinol and Palmitoylethanolamide) Drug Overview
 - 4.26.3 THX-110 (Dronabinol and Palmitoylethanolamide) Mechanism of Action
 - 4.26.4 THX-110 (Dronabinol and Palmitoylethanolamide) Licensing/Collaboration Companies
 - 4.26.5 THX-110 (Dronabinol and Palmitoylethanolamide) Clinical Trials
- 4.27 Tetrodotoxin (TTX) Drug Details
 - 4.27.1 Tetrodotoxin (TTX) Current Status
 - 4.27.2 Tetrodotoxin (TTX) Drug Overview
 - 4.27.3 Tetrodotoxin (TTX) Mechanism of Action
 - 4.27.4 Tetrodotoxin (TTX) Licensing/Collaboration Companies
 - 4.27.5 Tetrodotoxin (TTX) Clinical Trials

5. LATEST LOW BACK PAIN PIPELINE NEWS AND DEALS

6. APPENDIX

- 6.1 Our Databases and Reports
- 6.2 Research Methodolgy

I would like to order

Product name: 2020 Low Back Pain Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs

Product link: <https://marketpublishers.com/r/235090F50D0DEN.html>

Price: US\$ 1,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/235090F50D0DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

